R
ROKIT Healthcare
Organ regeneration platform using its proprietary 3D bio-fabrication technologies
About ROKIT Healthcare
ROKIT Healthcare, established in 2012 by founder and CEO Seok-Hwan You, is a South Korean biotechnology firm specializing in regenerative medicine. You, who previously served as an executive at Daewoo Motor and CEO of Celltrion Healthcare, founded the company with a vision to shift from imprecise medical treatments to personalized, regenerative solutions. The company has secured approximately $30 million in funding over three rounds, including a Series C in July 2020 led by DRADS Capital, and has since gone public on the KOSDAQ exchange.
The core of ROKIT Healthcare's business is its AI Hyper-Personalized Organ Regeneration Platform. This platform integrates AI-driven diagnostics with proprietary 4D bioprinting technology to create patient-specific therapies for tissue and organ regeneration. The primary business model involves providing its flagship "Dr. INVIVO" 4D bioprinters to hospitals and clinics, often free of charge, and generating revenue through the sale of single-use, patient-specific kits for each treatment. The process uses a patient's own (autologous) tissues, such as abdominal fat, to create a 'bio-ink', which is then used to print a regenerative patch. Because the material is sourced from the patient, the risk of immune rejection is eliminated.
The company's initial and most commercialized application is a skin regeneration platform for treating diabetic foot ulcers (DFU), a condition that can otherwise lead to amputation. This treatment has been successfully used in clinical trials and is being commercialized in numerous countries. Building on this success, ROKIT is expanding its platform to address other chronic conditions, including cartilage regeneration for osteoarthritis and a treatment for chronic kidney disease, which is currently in the clinical stage. These applications similarly use autologous tissue to create customized regenerative patches.
Beyond organ regeneration, ROKIT operates through two additional divisions. ROKIT America focuses on the anti-aging market, developing and selling bio-supplement products, most notably Nicotinamide Mononucleotide (NMN) supplements, which are designed to boost NAD+ levels to support cellular health and longevity. ROKIT Genomics offers advanced single-cell RNA sequencing (scRNA-seq) analysis as a service to researchers, government agencies, and institutions, providing support from experimental design to data analysis in fields like oncology and immunology.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2025
- Employees
- 70
- Open positions
- None listed
- Dealroom signal
- 52.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Regenerative Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Apr 2026 | $25M | — | MIGUAE | ↗ |
| POST IPO EQUITY✓Other financing | Mar 2026 | $52M | — | GVA Capital · Oasis Management · Milestone Asset Management · NH Investment & Securities | ↗ |
Growth signals
Latest recorded traffic for ROKIT Healthcare is 17K monthly website visits, up 0% over the last three months. ROKIT Healthcare's team grew 12.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
ROKIT Healthcare in the Seoul ecosystem
The ROKIT Healthcare office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Korea Venture Investment Corporation
Hana Financial Investment
DS Investment Solutions
Ascendo Ventures
Shinhan Financial Group
Tion
Series B and later9 investors entered at this stage
DRADS Capital
Genaxis- GCGVA Capital
Oasis Management- MMMilestone Asset Management
NH Investment & Securities
PAG
Weiss Asset Management
MIGUAE
Other known investors1 additional known investor
Nextrans Korea
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ROKIT Healthcare on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ROKIT Healthcare’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.


Rokit Healthcare to buy bankrupt Innopia Tech for $5.24M smart hospital push






